{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:22:39Z","timestamp":1783416159150,"version":"3.54.6"},"reference-count":21,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: As hyperbaric oxygen therapy has been sporadically used in combination with antimicrobial treatment for refractory infections in patients with hematologic malignancies, data on its efficacy and outcomes are limited. Methods: We retrospectively analyzed 55 patients with hematologic malignancies treated with hyperbaric oxygen therapy over a 10-year period at a single tertiary care center and report on patients\u2019 clinical features, infection types, treatment responses, and survival outcomes. Results: The most common underlying hematologic malignancy diagnosis was acute myeloid leukemia (30 patients, 55%). The most common hyperbaric oxygen therapy indications were invasive mold disease (IMD) (35 patients, 64%), BK virus-associated cystitis (17 patients, 31%), and bacterial cellulitis (3 patients, 5%). Patients underwent a median of 10 hyperbaric oxygen therapy sessions (range, 1\u201345). In total, 54 (98%) of the 55 patients were evaluable for response, of whom 32 (59%) patients demonstrated a response, defined as either resolution or stabilization of the infection. Among the 35 patients with IMDs, we found that 11 patients (31%) achieved a complete response, 5 (14%) had a partial response, 6 (17%) had stable disease, and 13 (37%) patients experienced progression of their infection. In contrast, among the 17 patients with BK virus-associated cystitis, 9 patients (53%) had persistent or worsening hematuria. The two evaluable patients with bacterial cellulitis responded with resolution of the infection. We reviewed the status of the hematologic malignancies at the time of hyperbaric oxygen therapy treatment and found that the 21 patients whose hematologic malignancies were in remission tended to have a higher response rate of their infection compared to patients whose hematologic malignancies were not in remission (73% vs. 46% p = 0.057). Despite the response of infections, 1-year mortality in these patients remained high at 76%. Conclusions: Based on our experience, hyperbaric oxygen therapy, in conjunction with appropriate anti-infective therapy and debridement surgery, could benefit selected patients with hematologic malignancies, especially those whose underlying disease is controlled but experience recalcitrant bacterial or fungal infections.<\/jats:p>","DOI":"10.3390\/cancers18132172","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:04:49Z","timestamp":1783411489000},"page":"2172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunct Hyperbaric Oxygen Therapy for Refractory Infections in Patients with Hematologic Malignancies: A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Kunhwa","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-2940","authenticated-orcid":false,"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hycienth","family":"Ahaneku","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-3263","authenticated-orcid":false,"given":"Deborah","family":"McCue","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-8804","authenticated-orcid":false,"given":"Javier","family":"Adachi","sequence":"additional","affiliation":[{"name":"Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-4193","authenticated-orcid":false,"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1056\/NEJM199606203342506","article-title":"Hyperbaric-oxygen therapy","volume":"334","author":"Tibbles","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"9","article-title":"Hyperbaric oxygen therapy","volume":"2","author":"Shah","year":"2010","journal-title":"J. Am. Coll. Certif. Wound Spec."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.biopha.2018.10.142","article-title":"Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections","volume":"109","author":"Memar","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e44893","DOI":"10.1097\/MD.0000000000044893","article-title":"Hematological safety of hyperbaric oxygen therapy in oncology: Stratified analysis by chemotherapy and herbal medicine use","volume":"104","author":"Woo","year":"2025","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chen, C.-L., Wang, S.-T., Cheng, W.-C., Wu, B.-R., Liao, W.-C., and Hsu, W.-H. (2023). Outcomes and Prognostic Factors in Critical Patients with Hematologic Malignancies. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030958"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mph.0000163215.37147.13","article-title":"Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: A 13-year longitudinal observational study","volume":"27","author":"Lackner","year":"2005","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2019.05.028","article-title":"Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation","volume":"25","author":"Abdelhakim","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Logan, C., Koura, D., and Taplitz, R. (2020). Updates in infection risk and management in acute leukemia. Hematol. Am. Soc. Hematol. Educ. Program, 135\u2013139.","DOI":"10.1182\/hematology.2020000098"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wade, J.C. (2006). Viral Infections in Patients with Hematological Malignancies. Hematol. Am. Soc. Hematol. Educ. Program, 368\u2013374.","DOI":"10.1182\/asheducation-2006.1.368"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/cir492","article-title":"Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: Neutropenia, humoral, and splenic defects","volume":"53","author":"Safdar","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","first-page":"12","article-title":"ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients","volume":"73","author":"Cesaro","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","first-page":"355","article-title":"Hyperbaric oxygen in the treatment of invasive fungal infections: A single-center experience","volume":"9","author":"Segal","year":"2007","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","article-title":"Hyperbaric oxygen as an adjunctive treatment for zygomycosis","volume":"11","author":"John","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Reasearch and Treatment of Cancer Consensus Criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","article-title":"EORTC\/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group","volume":"72","author":"Bassetti","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bmt.2011.228","article-title":"Clinical effectiveness of hyperbaric oxygen therapy for BK-virus-associated hemorrhagic cystitis after allogeneic bone marrow transplantation","volume":"47","author":"Sousa","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/tid.12266","article-title":"Successful hyperbaric oxygen therapy for refractory BK virus-associated hemorrhagic cystitis after cord blood transplantation","volume":"16","author":"Hosokawa","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.leukres.2008.06.018","article-title":"Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: Case report and review of literature","volume":"33","author":"Focosi","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhou, Y., Jia, Y., Wang, T., and Meng, D. (2023). Adverse effects of hyperbaric oxygen therapy: A systematic review and meta-analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1160774"},{"key":"ref_21","unstructured":"Asher, A., Contreary, C., Coppersmith, J., Haile, G., and Chen, T. (2019). Evaluation of the Medicare Prior Authorization Model for Non-emergent Hyperbaric Oxygen (HYPERBARIC OXYGEN THERAPY): Final Report, Mathematica Policy Research."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:43:27Z","timestamp":1783413807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":21,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132172"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132172","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}